Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Screening Criteria~  * Male or non-pregnant female ≥18 years of age~ * Rutherford Clinical Category 2-4~ * Clinical diagnosis of PAD requiring revascularization, secondary to atherosclerosis affecting a lower limb~ * Patient is willing to provide informed consent and comply with the required follow up visits, testing schedule, and medication regimen~* Procedural Criteria~  * De novo or nonstented restenotic lesions \>90 days from prior angioplasty and/or atherectomy, at least 3 cm from any previously placed stent or vascular surgery site~ * \>70% diameter stenosis up to 15 cm in total length (with no greater than 3 cm length of contiguous intervening normal artery) in the superficial femoral and/or popliteal artery (between the profunda and tibioperoneal trunk)~ * Reference vessel diameter ≥3mm and ≤ 8mm~ * Successful wire crossing of lesion~ * A patent artery proximal to the index lesion free from significant stenosis (significant stenosis is defined as \>50% in iliac or \>30% stenosis in common femoral artery) as confirmed by angiography (treatment of target lesion after successful treatment of iliac or common femoral artery lesions is acceptable)~Exclusion Criteria:~* Screening Criteria~  * Pregnant, nursing or planning on becoming pregnant in \< 2 years~ * Life expectancy of \<2 years~ * Known active malignancy~ * History of solid organ transplantation~ * Patient actively participating in another investigational device or drug study~ * History of hemorrhagic stroke within 3 months~ * Previous or planned surgical or interventional procedure within 30 days of index procedure~ * Chronic renal insufficiency with eGFR \<29~ * Prior bypass surgery, stenting of the target lesion~ * Inability to take required study medications~ * Contra-indication or known hypersensitivity to dexamethasone sodium phosphate, contrast media, or Physician prescribed antiplatelet regimen as indicated~ * Systemic fungal infection~ * Anticipated use of IIb/IIIa inhibitor prior to index lesion treatment~ * Acute or sub-acute thrombus, acute vessel occlusion or sudden symptom onset~ * Acute limb ischemia~ * Prior participation of the index limb in the current study (contralateral treatment is allowed)~ * Inability to ambulate (e.g. from prior ipsilateral or contralateral amputation)~ * Patient is receiving steroids already, however locally acting inhaled steroids for asthma treatment do not exclude patients from the trial~* Procedural Criteria~  * Lesions extending into the trifurcation or above the profunda~ * Heavy eccentric or moderate circumferential calcification at index lesion, which in the judgment of the investigator would prevent penetration of the Micro-Infusion Catheter needle through the vessel wall~ * Lesion length is \>15 cm as measured from proximal normal vessel to distal normal vessel, or there is no normal proximal arterial segment in which duplex ultrasound velocity ratios can be measured~ * Inadequate distal outflow defined as absence of at least one patent tibial artery (no lesion \>50% stenosis) with flow into the foot~ * Use of adjunctive therapies other than angioplasty, atherectomy (mechanical or laser) or bare metal stenting (i.e. scoring/cutting balloon, drug-eluting stent, drug-coated balloon, cryoplasty, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adventitial Dexamethasone (Type: EXPERIMENTAL): In patients receiving either angioplasty or atherectomy-based revascularization (pre-stratified to each by 50% of the total study), dexamethasone will be delivered to the adventitia following revascularization.

Based on this trial design, predict the completion outcome and termination type (if applicable).